Opinion|Videos|August 22, 2024
Impact of CAR T-cell therapy in Earlier Lines of MM
Author(s)Rafael Fonseca, MD, Binod Dhakal, MD, MS
A panel of experts examines the impact and potential of CAR T-cell therapy in earlier treatment lines for multiple myeloma, evaluating its efficacy, safety.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s talk about the use of CAR T-cell therapy in early R/R MM. Please share your thoughts on the following data:
- CARTITUDE-4
- KarMMa-3
- How does the CAR T-cell fit into 2nd line treatment in your practice and in which patients do you use CAR T-cell in?
- How does CAR T-cell therapy in the 2nd line affect your approach to front-line therapy for MM?
Advertisement
Related to this article
C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
2
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
3
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
4
Referral Barriers to Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
5